Login to Your Account



Mucosis lays battle plans for RSV's front line: The nose

By Michael Fitzhugh
Staff Writer

Wednesday, March 25, 2015
Mucosis BV, a Dutch company developing mucosal vaccines that can be applied needle-free via the nose or mouth, is rapidly advancing toward clinical studies that could pave the way for the arrival of broad-based and durable protection from respiratory syncytial virus (RSV).

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription